CY1108234T1 - Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη - Google Patents

Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη

Info

Publication number
CY1108234T1
CY1108234T1 CY20081100809T CY081100809T CY1108234T1 CY 1108234 T1 CY1108234 T1 CY 1108234T1 CY 20081100809 T CY20081100809 T CY 20081100809T CY 081100809 T CY081100809 T CY 081100809T CY 1108234 T1 CY1108234 T1 CY 1108234T1
Authority
CY
Cyprus
Prior art keywords
glucan
antibodies
protective
presented
glycan
Prior art date
Application number
CY20081100809T
Other languages
Greek (el)
English (en)
Inventor
Luciano Polonelli
Antonio Cassone
Original Assignee
Luciano Polonelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luciano Polonelli filed Critical Luciano Polonelli
Publication of CY1108234T1 publication Critical patent/CY1108234T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/10—Peptides being immobilised on, or in, an organic carrier the carrier being a carbohydrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CY20081100809T 2002-05-15 2008-07-31 Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη CY1108234T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
EP03730424A EP1506009B1 (en) 2002-05-15 2003-05-15 Beta-glucan-based anti-fungal vaccines

Publications (1)

Publication Number Publication Date
CY1108234T1 true CY1108234T1 (el) 2014-02-12

Family

ID=9936711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100809T CY1108234T1 (el) 2002-05-15 2008-07-31 Αντι-μυκητικα εμβολια βασιζομενα σε βητα-γλυκανη

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1506009B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE497781T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2830619A1 (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60336027D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
DE602005027830D1 (de) * 2004-04-05 2011-06-16 Univ Bordeaux 2 Peptide und peptidmimetika die an cd23 binden
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
LT2351578T (lt) * 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Vakcinų gavimo būdas
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2007084661A2 (en) * 2006-01-17 2007-07-26 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
JP6082174B2 (ja) * 2006-11-06 2017-02-15 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ 免疫調節組成物及びその使用方法
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
AU2009243094B2 (en) * 2006-11-06 2015-02-12 Massachusetts Institute Of Technology Immunomodulating compositions and methods of use thereof
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
WO2009077854A2 (en) * 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US9439954B2 (en) 2007-11-26 2016-09-13 Glaxosmithkline Biologicals Sa Conjugated beta-1,3-linked glucans
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
BRPI1008984A2 (pt) * 2009-03-10 2016-07-05 Palmed Teva Ltd novas e distintas variedades de cogumelos basidiomycotas superiores, biomassa de cogumelo, biomassa micelial, extrato de um cogumelo, cultura micelial submersa pura de coprinus comatus, cultura micelial submersa pura de tremella mesentérica, b-glucano de baixo peso molecular solúvel em água 3,4 b-glucano linear insolúvel em água obtiodo a partir de tremella mesentérica, glucuronixilomanano obtido a partir de tremella mesentérica, suplemento alimentar, comida para animais, composição farmacêutica e composição agrícola.
US8858958B2 (en) 2009-08-27 2014-10-14 Novartis Ag Adjuvant comprising aluminum, oligonucleotide and polycation
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
KR101440818B1 (ko) * 2010-05-14 2014-11-03 알테크 인코포레이티드 효모 세포벽 성분들 및 이의 검출
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
EP2652511B8 (en) 2010-12-14 2017-06-28 GlaxoSmithKline Biologicals SA Flow cytometry analysis of materials adsorbed to metal salts
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
WO2013068949A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
DK2822947T3 (en) 2012-03-07 2016-09-19 Glaxosmithkline Biologicals Sa ARGINAL SALTS OF A TLR-7 AGONIST
CN104519910B (zh) 2012-03-07 2017-05-03 诺华股份有限公司 肺炎链球菌抗原的含佐剂制剂
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP3363462A1 (en) * 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
AU2014241492A1 (en) * 2013-03-12 2015-09-17 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
BR112016000585A2 (pt) 2013-07-11 2018-03-20 Novartis Ag modificações quimioenzimáticas sítio-específicas de proteína
CN106170698A (zh) * 2013-12-05 2016-11-30 生物治疗公司 β‑葡聚糖测定方法
CA2973617A1 (en) * 2015-01-26 2016-08-04 Kaleido Biosciences, Inc. Glycan therapeutics and related methods thereof
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
CA3088832A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec B.V. & Co. KG Regulatory t cell expressing a chimeric antigen receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
US20250186596A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN
US20250186580A1 (en) 2022-02-28 2025-06-12 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
CA2066172A1 (en) * 1989-09-08 1991-03-09 Alpha Beta Technology, Inc. Method for producing soluble glucans
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2231770T3 (es) * 1993-03-05 2005-05-16 Wyeth Holdings Corporation Nuevos plasmidos para la produccion de proteina crm y toxina difterica.
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) * 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
WO1999055715A2 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Also Published As

Publication number Publication date
JP2010131017A (ja) 2010-06-17
CA2830619A1 (en) 2003-11-27
ES2306871T3 (es) 2008-11-16
CA2485847A1 (en) 2003-11-27
JP2012224636A (ja) 2012-11-15
WO2003097091A2 (en) 2003-11-27
JP5110767B2 (ja) 2012-12-26
DK1506009T3 (da) 2008-09-01
DE60320979D1 (de) 2008-06-26
DE60336027D1 (de) 2011-03-24
EP1891970A1 (en) 2008-02-27
US20070141088A1 (en) 2007-06-21
EP1891970B1 (en) 2011-02-09
US8679506B2 (en) 2014-03-25
CA2485847C (en) 2013-12-31
AU2003241104A1 (en) 2003-12-02
HK1069125A1 (en) 2005-05-13
GB0211118D0 (en) 2002-06-26
ATE395080T1 (de) 2008-05-15
ATE497781T1 (de) 2011-02-15
US7824688B2 (en) 2010-11-02
EP1506009A2 (en) 2005-02-16
EP1506009B1 (en) 2008-05-14
SI1506009T1 (sl) 2008-10-31
US20050208079A1 (en) 2005-09-22
US8398990B2 (en) 2013-03-19
PT1506009E (pt) 2008-08-14
JP2005535298A (ja) 2005-11-24
US20130171187A1 (en) 2013-07-04
US20110059120A1 (en) 2011-03-10
WO2003097091A3 (en) 2004-03-04
JP5684758B2 (ja) 2015-03-18
HK1114335A1 (en) 2008-10-31

Similar Documents

Publication Publication Date Title
DK1506009T3 (da) Beta-glucan-baserede antisvampevacciner
NZ511201A (en) Use of paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
DE60036915D1 (de) Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
PT1121127E (pt) Composicoes farmaceuticas orais contendo buprenorfina
WO2005007103A3 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
WO2004113422A3 (en) Drug delivery device comprising an active compound and method for releasing an active compound from a drug delivery device
DE60119143D1 (de) Körperpflegemittel
DK1187611T3 (da) Oftalmiske histaminholdige sammensætninger og anvendelse deraf
WO2003099241A3 (en) Sunscreen compositions and methods of use thereof
ES2172390B1 (es) Composiciones plaguicidas.
AU4747497A (en) Sordarin derivatives
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
ID26929A (id) Fungisida
PL338678A1 (en) Derivatives of 4-cyano-4-deformylsordacin
EP0943339A3 (en) Method of preventing allograft rejection
EA200000248A1 (ru) Производные 4-циано-4-деформилсордарина
RU2001100069A (ru) Антгельминтное средство
CA3295831A1 (en) Formulation comprising antibody-drug conjugate targeting claudin18.2, method for preparing the same, and use thereof
IL169784A0 (en) Spermicidal and fungicidal compositions containing hexahydroindenopyridine derivatives and methods utilizing the same
TR200002675T2 (tr) Paroksetinin kristalin formu.
CY1106500T1 (el) Μυκητοκτονα μιγματα
杨俊杰 The Funny Millionaire
RU99118348A (ru) Средство для подавления роста сульфатвосстанавливающих бактерий